TABLE 1.
In vitro antimalarial activities of salinomycin, monensin, and nigericin against asexual P. falciparum parasites
| Drug | IC50 (nM) for strain (mean ± SD)a: |
||||
|---|---|---|---|---|---|
| D10 | W2 | 3D7 | Ghana | Burkina Faso | |
| Salinomycin | 39.6 ± 1.1 | 26.3 ± 11.4 | 21.9 ± 12.3 | 30.7 ± 4.0 | 50.0 ± 2.1 |
| Monensin | 0.5 ± 0.1 | 0.5 ± 0.2 | 1.0 ± 0.2 | NTb | NT |
| Nigericin | 1.9 ± 0.6 | 1.8 ± 0.1 | 1.8 ± 1.0 | NT | NT |
| CQc | 18.6 ± 6.6 | 255.7 ± 77.8 | 11.0 ± 5.4 | 15.8 ± 2.0 | 146.4 ± 31.0 |
| DHAc | 5.6 ± 1.1 | 2.1 ± 0.3 | 2.8 ± 0.7 | 0.6 ± 0.5 | 1.7 ± 0.3 |
a
Data are from three different experiments performed in duplicate. P. falciparum strains D10 and 3D7 (CQ sensitive), strain W2 (CQ resistant), and two isolates (not clonal) from different patients coming from Ghana and Burkina Faso were used in this study.
b
NT, not tested.
c
Chloroquine (CQ) and dihydroartemisinin (DHA) were used as positive controls.